Extrait

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).

Critère d'inclusion

• pulmonary hypertension

Liens

• ictrp
• nct